請用此 Handle URI 來引用此文件：
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/20160完整後設資料紀錄
| DC 欄位 | 值 | 語言 |
|---|---|---|
| dc.contributor.advisor | 方啟泰(Chi-Tai Fang) | |
| dc.contributor.author | Yi-Le Li | en |
| dc.contributor.author | 李奕樂 | zh_TW |
| dc.date.accessioned | 2021-06-08T02:41:11Z | - |
| dc.date.copyright | 2018-03-07 | |
| dc.date.issued | 2018 | |
| dc.date.submitted | 2018-02-13 | |
| dc.identifier.citation | 1. Organization, W.H., Global tuberculosis report 2017. 2017.
2. 行政院衛生署, 結核病十年減半全民動員計畫. 2006. 3. 周志浩、莊人祥、羅一鈞、陳穎慧、黃彥芳、朱柏威、王若珊、黃淑華、楊祥麟, 台灣結核病防治年報Taiwan Tuberculosis Control Report 2015. 2017. 4. Organization, W.H., Guidelines for establishing DOTS-PLUS pilot projects for the management of multidrug-resistant tuberculosis (MDR-TB) Scientific Panel of the Working Group on DOTS-Plus for MDR-TB. 2000. 5. Belard, S., et al., Bedaquiline for the treatment of drug-resistant tuberculosis. Expert Rev Anti Infect Ther, 2015. 13(5): p. 535-53. 6. Gler, M.T., et al., Delamanid for multidrug-resistant pulmonary tuberculosis. N Engl J Med, 2012. 366(23): p. 2151-60. 7. Ahuja, S.D., et al., Multidrug resistant pulmonary tuberculosis treatment regimens and patient outcomes: an individual patient data meta-analysis of 9,153 patients. PLoS Med, 2012. 9(8): p. e1001300. 8. 衛生福利部疾病管制署編, 結核病診治指引(第六版) Taiwan Guidelines for TB Diagnosis & Treatment. 2017. 9. 楊文達，黃丞正, 多重抗藥性結核病之現況, in 內科學誌. 2013. p. 357-365. 10. Aung, K.J., et al., Successful '9-month Bangladesh regimen' for multidrug-resistant tuberculosis among over 500 consecutive patients. Int J Tuberc Lung Dis, 2014. 18(10): p. 1180-7. 11. Moodley, R., T.R. Godec, and S.T. Team, Short-course treatment for multidrug-resistant tuberculosis: the STREAM trials. Eur Respir Rev, 2016. 25(139): p. 29-35. 12. Zhao, M., et al., Transmission of MDR and XDR tuberculosis in Shanghai, China. PLoS One, 2009. 4(2): p. e4370. 13. Gelmanova, I.Y., et al., Barriers to successful tuberculosis treatment in Tomsk, Russian Federation: non-adherence, default and the acquisition of multidrug resistance. Bull World Health Organ, 2007. 85(9): p. 703-11. 14. Gandhi, N.R., et al., Nosocomial transmission of extensively drug-resistant tuberculosis in a rural hospital in South Africa. J Infect Dis, 2013. 207(1): p. 9-17. 15. Royce, S., et al., Multidrug resistance in new tuberculosis patients: burden and implications. Int J Tuberc Lung Dis, 2013. 17(4): p. 511-3. 16. Kendall, E.A., M.O. Fofana, and D.W. Dowdy, Burden of transmitted multidrug resistance in epidemics of tuberculosis: a transmission modelling analysis. Lancet Respir Med, 2015. 3(12): p. 963-72. 17. Clark, T.G., et al., Elucidating emergence and transmission of multidrug-resistant tuberculosis in treatment experienced patients by whole genome sequencing. PLoS One, 2013. 8(12): p. e83012. 18. Trauer, J.M., et al., Risk of Active Tuberculosis in the Five Years Following Infection . . . 15%? Chest, 2016. 149(2): p. 516-525. 19. Lin, P.L., et al., Quantitative comparison of active and latent tuberculosis in the cynomolgus macaque model. Infect Immun, 2009. 77(10): p. 4631-42. 20. Barry, C.E., 3rd, et al., The spectrum of latent tuberculosis: rethinking the biology and intervention strategies. Nat Rev Microbiol, 2009. 7(12): p. 845-55. 21. Seddon, J.A., et al., Management of children exposed to multidrug-resistant Mycobacterium tuberculosis. Lancet Infect Dis, 2012. 12(6): p. 469-79. 22. Pai, M., A. Zwerling, and D. Menzies, Systematic review: T-cell-based assays for the diagnosis of latent tuberculosis infection: an update. Ann Intern Med, 2008. 149(3): p. 177-84. 23. Marks, G.B., et al., The incidence of tuberculosis in a cohort of South-East Asian refugees arriving in Australia 1984-94. Respirology, 2001. 6(1): p. 71-4. 24. Zak, D.E., et al., A blood RNA signature for tuberculosis disease risk: a prospective cohort study. Lancet, 2016. 387(10035): p. 2312-2322. 25. Shah, N.S., et al., Yield of contact investigations in households of patients with drug-resistant tuberculosis: systematic review and meta-analysis. Clin Infect Dis, 2014. 58(3): p. 381-91. 26. O'Donnell, M.R., et al., High incidence of hospital admissions with multidrug-resistant and extensively drug-resistant tuberculosis among South African health care workers. Ann Intern Med, 2010. 153(8): p. 516-22. 27. Gandhi, N.R., et al., Extensively drug-resistant tuberculosis as a cause of death in patients co-infected with tuberculosis and HIV in a rural area of South Africa. Lancet, 2006. 368(9547): p. 1575-80. 28. Grandjean, L., et al., Transmission of Multidrug-Resistant and Drug-Susceptible Tuberculosis within Households: A Prospective Cohort Study. PLoS Med, 2015. 12(6): p. e1001843; discussion e1001843. 29. Becerra, M.C., et al., Tuberculosis burden in households of patients with multidrug-resistant and extensively drug-resistant tuberculosis: a retrospective cohort study. Lancet, 2011. 377(9760): p. 147-52. 30. Albert, H., et al., Development, roll-out and impact of Xpert MTB/RIF for tuberculosis: what lessons have we learnt and how can we do better? Eur Respir J, 2016. 48(2): p. 516-25. 31. Organization, W.H., WHO Treatment Guidelines for Drug-Resistant Tuberculosis, 2016 Update, in WHO Treatment Guidelines for Drug-Resistant Tuberculosis, 2016 Update. 2016: Geneva. 32. Barrera, E., V. Livchits, and E. Nardell, F-A-S-T: a refocused, intensified, administrative tuberculosis transmission control strategy. Int J Tuberc Lung Dis, 2015. 19(4): p. 381-4. 33. Organization, W.H., Recommendations for investigating contacts of persons with infectious tuberculosis in low- and middle-income countries. 2012. 34. Organization, W.h., Systematic screening for active tuberculosis: principles and recommendations. 2013. 35. Dowdy, D.W., S. Basu, and J.R. Andrews, Is passive diagnosis enough? The impact of subclinical disease on diagnostic strategies for tuberculosis. Am J Respir Crit Care Med, 2013. 187(5): p. 543-51. 36. Lacoma, A., et al., GenoType MTBDRsl for molecular detection of second-line-drug and ethambutol resistance in Mycobacterium tuberculosis strains and clinical samples. J Clin Microbiol, 2012. 50(1): p. 30-6. 37. Van't Hoog, A.H., et al., The potential of a multiplex high-throughput molecular assay for early detection of first and second line tuberculosis drug resistance mutations to improve infection control and reduce costs: a decision analytical modeling study. BMC Infect Dis, 2015. 15: p. 473. 38. Dharmadhikari, A.S., et al., Rapid impact of effective treatment on transmission of multidrug-resistant tuberculosis. Int J Tuberc Lung Dis, 2014. 18(9): p. 1019-25. 39. Sinanovic, E., et al., Impact of reduced hospitalisation on the cost of treatment for drug-resistant tuberculosis in South Africa. Int J Tuberc Lung Dis, 2015. 19(2): p. 172-8. 40. Horter, S., et al., 'Home is where the patient is': a qualitative analysis of a patient-centred model of care for multi-drug resistant tuberculosis. BMC Health Serv Res, 2014. 14: p. 81. 41. Cox, H., et al., Community-based treatment of drug-resistant tuberculosis in Khayelitsha, South Africa. Int J Tuberc Lung Dis, 2014. 18(4): p. 441-8. 42. Loveday, M., et al., Community-based care vs. centralised hospitalisation for MDR-TB patients, KwaZulu-Natal, South Africa. Int J Tuberc Lung Dis, 2015. 19(2): p. 163-71. 43. Kamat, S.R., et al., A controlled study of the influence of segregation of tuberculous patients for one year on the attack rate of tuberculosis in a 5-year period in close family contacts in South India. Bull World Health Organ, 1966. 34(4): p. 517-32. 44. NICE, Tuberculosis. Clinical diagnosis and management of tuberculosis, and measures for its prevention and control. 2011. 45. Organization, W.H., Guidelines for the programmatic management of drug-resistant tuberculosis. 2011. 46. Bantubani, N., et al., High rates of potentially infectious tuberculosis and multidrug-resistant tuberculosis (MDR-TB) among hospital inpatients in KwaZulu Natal, South Africa indicate risk of nosocomial transmission. PLoS One, 2014. 9(3): p. e90868. 47. Bates, M., et al., Evaluation of the burden of unsuspected pulmonary tuberculosis and co-morbidity with non-communicable diseases in sputum producing adult inpatients. PLoS One, 2012. 7(7): p. e40774. 48. Organization, W.H., WHO Policy on TB Infection Control in Health-Care Facilities, Congregate Settings and Households. 2009. 49. Escombe, A.R., et al., Upper-room ultraviolet light and negative air ionization to prevent tuberculosis transmission. PLoS Med, 2009. 6(3): p. e43. 50. Dharmadhikari, A.S., et al., Surgical face masks worn by patients with multidrug-resistant tuberculosis: impact on infectivity of air on a hospital ward. Am J Respir Crit Care Med, 2012. 185(10): p. 1104-9. 51. Chen, S.K., et al., Evaluation of single-use masks and respirators for protection of health care workers against mycobacterial aerosols. Am J Infect Control, 1994. 22(2): p. 65-74. 52. Migliori, G.B., et al., TB and MDR/XDR-TB in European Union and European Economic Area countries: managed or mismanaged? Eur Respir J, 2012. 39(3): p. 619-25. 53. Arend, S.M. and D. van Soolingen, Editorial commentary: genotyping of Mycobacterium tuberculosis in China and missing links in the chain of ongoing transmission of tuberculosis. Clin Infect Dis, 2015. 61(2): p. 228-32. 54. Frieden, T.R., et al., Tuberculosis in New York City--turning the tide. N Engl J Med, 1995. 333(4): p. 229-33. 55. Organization, W.H., Guidelines on the management of latent tuberculosis infection. 2015. 56. Bamrah, S., et al., Treatment for LTBI in contacts of MDR-TB patients, Federated States of Micronesia, 2009-2012. Int J Tuberc Lung Dis, 2014. 18(8): p. 912-8. 57. Seddon, J.A., et al., Preventive therapy for child contacts of multidrug-resistant tuberculosis: a prospective cohort study. Clin Infect Dis, 2013. 57(12): p. 1676-84. 58. Schaaf, H.S., et al., Evaluation of young children in contact with adult multidrug-resistant pulmonary tuberculosis: a 30-month follow-up. Pediatrics, 2002. 109(5): p. 765-71. 59. Torre-Cisneros, J., et al., Tuberculosis prophylaxis with levofloxacin in liver transplant patients is associated with a high incidence of tenosynovitis: safety analysis of a multicenter randomized trial. Clin Infect Dis, 2015. 60(11): p. 1642-9. 60. Harvard, D.D.H.G.f.C.S.M., Post-Exposure Management of Multidrug-Resistant Tuberculosis Contacts: Evidence-Based Recommendations. 2015. 61. Health., C.I.T.C.a.C.D.o.P., Drug-resistant tuberculosis: A survival guide for clinicians, 3rd edition. 2016. 62. Investigators., V.-Q.M. V-QUIN MDR Trial. 2016; Available from: https://anzctr.org.au/Trial/Registration/TrialReview.aspx?id=369817. 63. McKenna, L. Momentum in the Pediatric Tuberculosis Treatment Pipeline. 2015; Available from: http://www.pipelinereport.org/2015/tb-pediatrics. 64. Trieu, L., D.C. Proops, and S.D. Ahuja, Moxifloxacin Prophylaxis against MDR TB, New York, New York, USA. Emerg Infect Dis, 2015. 21(3): p. 500-3. 65. Adler-Shohet, F.C., et al., Management of latent tuberculosis infection in child contacts of multidrug-resistant tuberculosis. Pediatr Infect Dis J, 2014. 33(6): p. 664-6. 66. Garcia-Prats, A.J., et al., Children exposed to multidrug-resistant tuberculosis at a home-based day care centre: a contact investigation. Int J Tuberc Lung Dis, 2014. 18(11): p. 1292-8. 67. Williams, B., et al., Management of pediatric contacts of multidrug resistant tuberculosis in the United Kingdom. Pediatr Infect Dis J, 2013. 32(8): p. 926-7. 68. Denholm, J.T., et al., Long-term follow-up of contacts exposed to multidrug-resistant tuberculosis in Victoria, Australia, 1995-2010. Int J Tuberc Lung Dis, 2012. 16(10): p. 1320-5. 69. Tochon, M., et al., Management of young children in contact with an adult with drug-resistant tuberculosis, France, 2004-2008. Int J Tuberc Lung Dis, 2011. 15(3): p. 326-30. 70. Attamna, A., et al., Risk of tuberculosis in close contacts of patients with multidrug resistant tuberculosis: a nationwide cohort. Thorax, 2009. 64(3): p. 271. 71. Feja, K., et al., Management of pediatric multidrug-resistant tuberculosis and latent tuberculosis infections in New York City from 1995 to 2003. Pediatr Infect Dis J, 2008. 27(10): p. 907-12. 72. Sneag, D.B., et al., Failure of chemoprophylaxis with standard antituberculosis agents in child contacts of multidrug-resistant tuberculosis cases. Pediatr Infect Dis J, 2007. 26(12): p. 1142-6. 73. Lou, H.X., M.A. Shullo, and T.P. McKaveney, Limited tolerability of levofloxacin and pyrazinamide for multidrug-resistant tuberculosis prophylaxis in a solid organ transplant population. Pharmacotherapy, 2002. 22(6): p. 701-4. 74. Papastavros, T., et al., Adverse events associated with pyrazinamide and levofloxacin in the treatment of latent multidrug-resistant tuberculosis. CMAJ, 2002. 167(2): p. 131-6. 75. Ridzon, R., et al., Asymptomatic hepatitis in persons who received alternative preventive therapy with pyrazinamide and ofloxacin. Clin Infect Dis, 1997. 24(6): p. 1264-5. 76. Schaaf, H.S. and B.J. Marais, Management of multidrug-resistant tuberculosis in children: a survival guide for paediatricians. Paediatr Respir Rev, 2011. 12(1): p. 31-8. 77. Abubakar, I., et al., Systematic review and meta-analysis of the current evidence on the duration of protection by bacillus Calmette-Guerin vaccination against tuberculosis. Health Technol Assess, 2013. 17(37): p. 1-372, v-vi. 78. 杜鴻運、蘇益仁. 臺灣結核菌基因型分布與族群遷移密切相關. 2014; Available from: http://www.nhri.org.tw/NHRI_WEB/nhriw001Action.do?status=Show_Dtl&nid=20140918973742890000&uid=20081204954976470000. 79. Luabeya, A.K., et al., First-in-human trial of the post-exposure tuberculosis vaccine H56:IC31 in Mycobacterium tuberculosis infected and non-infected healthy adults. Vaccine, 2015. 33(33): p. 4130-40. 80. Uplekar, M., et al., WHO's new end TB strategy. Lancet, 2015. 385(9979): p. 1799-1801. 81. Mitnick, C.D., et al., Programmatic Management of Drug-Resistant Tuberculosis: An Updated Research Agenda. PLoS One, 2016. 11(5): p. e0155968. 82. Maryandyshev, A., et al., Bedaquiline and Delamanid Combination Treatment of 5 Patients with Pulmonary Extensively Drug-Resistant Tuberculosis. Emerg Infect Dis, 2017. 23(10). 83. Svensson, E.M., et al., Rifampicin and rifapentine significantly reduce concentrations of bedaquiline, a new anti-TB drug. J Antimicrob Chemother, 2015. 70(4): p. 1106-14. 84. Xu, J., et al., Primary Clofazimine and Bedaquiline Resistance among Isolates from Patients with Multidrug-Resistant Tuberculosis. Antimicrob Agents Chemother, 2017. 61(6). 85. Organiozation, W.H., Frequently asked questions about the implementation of the new WHO recommendation on the use of the shorter MDR-TB regimen under programmatic conditions. 2016. 86. Mok, J.H., et al., Additional Drug Resistance Patterns among Multidrug-Resistant Tuberculosis Patients in Korea: Implications for Regimen Design. J Korean Med Sci, 2017. 32(4): p. 636-641. 87. Schwartzman, K., et al., Domestic returns from investment in the control of tuberculosis in other countries. N Engl J Med, 2005. 353(10): p. 1008-20. | |
| dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/20160 | - |
| dc.description.abstract | 預防多重抗藥性結核病（Multi-Drug Resistant Tuberculosis; MDR-TB）和超級抗藥性結核病（Extensively drug resistant tuberculosis, XDR-TB）是目前全球結核病控制的首要任務，我們受限於現有治療的高成本、感染到抗藥性結核病的病患需要忍受使用高毒性藥物和治療效果普遍不佳等限制來達成有效控制疫情的目標。為此我們進行了系統性文獻回顧，評估可降低預防多重抗藥性結核病（Multi-Drug Resistant Tuberculosis; MDR-TB）和超級抗藥性結核病（Extensively drug resistant tuberculosis, XDR-TB）傳播和疾病進展策略的證據。
能夠迅速發現並即時啟動有效的治療是消除多重抗藥性結核病（Multi-Drug Resistant Tuberculosis; MDR-TB）和超級抗藥性結核病（XDR-TB）病例為關鍵所在。快速分子檢測技術（rapid molecular testing technology）的發展改變了高發病地區的抗藥性鑑定與多重抗藥性結核病（Multi-Drug Resistant Tuberculosis; MDR-TB）和超級抗藥性結核病（Extensively drug resistant tuberculosis, XDR-TB）的能力，可以早期診斷指標個案與降低親密接觸者感染比例，進一步提供患者更好的結核病治療及預後，並加強公共衛生傳播防治，再者可以優化針對醫院和診所感染控制措施，保護其他患者和醫務人員，同時需要考慮如何實施具彈性與配合社區屬性的針對性篩檢作為以降低社區高發病地區的發病率。有關近期發展的短期處方籤進展與推廣及在感染抗藥性結核病的接觸者預防性投藥兩部分，我們找到了幾篇觀察性世代研究（cohort study）支持，有效的短期處方籤與預防性投藥治療可以降低抗藥結核病病程進展與擴大傳染的風險，但迫切需要隨機試驗來證實這些觀察結果。 我國規劃自2016年起啟動「我國加入WHO 2035消除結核」20年計畫，積極跟上世界的腳步，近年的防治成果更可做為執行防治的典範。本文期許可作為給有關當局制定相關防治政策之參考。 關鍵字：多重抗藥性結核病、接觸者預防性投藥 | zh_TW |
| dc.description.abstract | Prevention of Multi-Drug Resistant Tuberculosis (MDR-TB) and Extensively Drug-Resistant Tuberculosis (XDR-TB) is the first priority for global TB control. We consider restrictions like high cost of existing treatments, patients need to tolerate the use of highly toxic drugs and poor treatment effect, to achieve the goal of effectively controlling the epidemic. We conducted a systematic review of the literatures to assess evidence that provide a strategies for preventing the spread of multidrug resistant tuberculosis (MDR-TB) and extensively drug-resistant tuberculosis (XDR-TB). | en |
| dc.description.provenance | Made available in DSpace on 2021-06-08T02:41:11Z (GMT). No. of bitstreams: 1 ntu-107-R02847043-1.pdf: 1933290 bytes, checksum: 547e754a05567e6ff6b472657aa277a5 (MD5) Previous issue date: 2018 | en |
| dc.description.tableofcontents | 口試委員審定書 i
誌謝 ii 中文摘要 iii ABSTRACT iv 壹、 實習單位簡介 3 貳、 研究背景 5 一、我國近年結核病流行趨勢及防治政策 5 二、 抗藥性結核病簡介 7 (一) 全球抗藥性結核病疾病負擔概述 7 (二) 抗藥性結核病來源 8 (三) 抗藥性結核病分類 9 (四) 目前常使用之治療期程 10 參、 相關文獻回顧 11 一、我國公衛政策簡述 11 二、 短程治療處方簽與新藥物 13 肆、 研究方法 16 一、 研究論文回顧 16 二、 系統性回顧方式 16 (一) PubMed： 16 (二) Cochrane Database of Systematic Reviews： 16 (三) EMBASE： 17 (四) 搜尋結果 17 伍、 初級抗結核病菌傳染途徑簡介 19 陸、 在多重抗藥性結核病接觸者中結核病的傳染 21 柒、 有效抗藥性結核病控制策略的關鍵因素 23 (一) 早期發現 23 (二) 實施有效的治療 24 (三) 加強感控措施 24 (四) 進行接觸者的調查 25 (五) 進行預防性治療 26 (六) 疫苗的研發 31 (七) 未來研發方向 31 捌、 有效療法的補充說明 33 一、 抗藥性結核病新藥發展 33 (一) Bedaquiline 33 (二) Delamanid 33 (三) Pretomanid 34 二、 抗藥性結核病短程治療法 34 玖、 結論 37 參考文獻 38 | |
| dc.language.iso | zh-TW | |
| dc.title | 多重抗藥性結核防治策略：系統性文獻回顧 | zh_TW |
| dc.title | Prevention and Control Strategies of Multi-Drug Resistant
Tuberculosis：A Systematic Review | en |
| dc.type | Thesis | |
| dc.date.schoolyear | 106-1 | |
| dc.description.degree | 碩士 | |
| dc.contributor.oralexamcommittee | 顏哲傑(Jer-Jea Yen),江振源(Chen-Yuan Chiang),詹佩君(Pei-Chun Chan) | |
| dc.subject.keyword | 多重抗藥性結核病,接觸者預防性投藥, | zh_TW |
| dc.subject.keyword | multidrug resistant tuberculosis,MDR-TB, | en |
| dc.relation.page | 42 | |
| dc.identifier.doi | 10.6342/NTU201800531 | |
| dc.rights.note | 未授權 | |
| dc.date.accepted | 2018-02-13 | |
| dc.contributor.author-college | 公共衛生學院 | zh_TW |
| dc.contributor.author-dept | 公共衛生碩士學位學程 | zh_TW |
| 顯示於系所單位： | 公共衛生碩士學位學程 | |
文件中的檔案：
| 檔案 | 大小 | 格式 | |
|---|---|---|---|
| ntu-107-1.pdf 未授權公開取用 | 1.89 MB | Adobe PDF |
系統中的文件，除了特別指名其著作權條款之外，均受到著作權保護，並且保留所有的權利。